NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
J Natl Compr Canc Netw
; 17(6): 650-661, 2019 06 01.
Article
em En
| MEDLINE
| ID: mdl-31200358
ABSTRACT
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfoma Folicular
/
Linfoma Difuso de Grandes Células B
/
Oncologia
/
Recidiva Local de Neoplasia
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article